Clinical trials: Generations
Cardiac Surgical Procedures
Lead Extract Study
The recent expansion of indications for implantable cardioverter defibrillators (ICDs) has changed the population of patients being implanted.
- Trial name
- EXTRACT (NCT01169441)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- St. Paul Heart Clinic
BCL2 Gene mRNA Overexpression
Validation of Useful Markers Generated by Next Generation Bio-data Based Genome Research and Cohort Study
Multiple biomarker development through validation of useful markers generated by next generation bio-data based genome research and cohort study
- Trial name
- miRNA_Chip (NCT02807896)
- Where
- South Korea
- Volunteers
- 232 people, healthy volunteers welcome
- Sponsor
- CHANGHEE LEE
Myofascial Pain Syndrome
New Generation Low Level Laser Effect in Myofacial Pain Syndrome
Low level laser treatments have been used to treat painful trigger points in myofascial pain syndrome (MPS), but the effectiveness of the appropriate laser type and parameters is still uncertain.
- Trial name
- NCT06442553
- Testing
- GRR laser, Nd:YAG laser
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- University of Gaziantep
Lymphangioleiomyomatosis (LAM), Extracellular Vesicles; Generation and Function
Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex
Lymphangioleiomyomatosis (LAM) is a rare lung disease, linked to Tuberous Sclerosis Complex (TSC) or occurring sporadically, and involves abnormal mTORC1 activation.
- Trial name
- NCT07304856
- Testing
- Pulmonary Function Test, Analysis of Extracellular Vesicles
- Where
- Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- University of Milan
Coronary Artery Disease
Comparison of Low-radiation Dose CT Angiography With Invasive Coronary Angiography in Stable Coronary Disease
This study is evaluating the performance of modern CT coronar angiography with low radiation technique compared to conventional invasive coronar angiography.
- Trial name
- NCT01476579
- Testing
- Cardiac Computer Tomography
- Where
- Norway
- Volunteers
- 769 people
- Sponsor
- University Hospital of North Norway
Symptomatic Severe Aortic Stenosis
Portico Next Generation Approval Study
The purpose of this clinical study is to evaluate the acute safety and effectiveness of the next-generation Navitor (Portico™ NG) Transcatheter Aortic Heart Valve as assessed by the rate of all-cause mortality at 30 days and the…
- Trial name
- NCT04011722
- Testing
- Portico™ NG (Navitor) Valve and FlexNav™ Delivery System, Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System
- Where
- 28 sites in United States, Australia and 3 more
- Volunteers
- 333 people
- Sponsor
- Abbott Medical Devices
HIV, HIV Associate Weight Loss
Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI
Patients who developed metabolic syndrome after initiation of HIV treatment or with antiretroviral therapy (ART) for at least 36 months, treated with second generation integrase inhibitors (BIC/TAF/FTC, DTG/ABC/3Tc or…
- Conditions
- HIV, HIV Associate Weight Loss, HIV-1 Infection, Integrase Inhibitors, HIV; HIV PROTEASE INHIB
- Trial name
- TLATOANI (NCT06602622)
- Testing
- Integrase inhibitor, Doravirine + tenofovir DF + lamivudine
- Where
- 2 sites in Mexico
- Volunteers
- 108 people
- Sponsor
- Instituto Mexicano del Seguro Social
VAP - Ventilator Associated Pneumonia
Early Identification of Pathogens in Children With Respiratory Tract Infection by Mechanical Ventilation Using mNGS
VAP（Ventilator-associated pneumonia）is the most common complication of mechanical ventilation in severely ill patients. VAP is defined as pneumonia occurring 48 hours after patients receive mechanical ventilation, including…
- Trial name
- NCT04955821
- Testing
- mNGS diagnose of VAP
- Volunteers
- 400 people
- Sponsor
- Children's Hospital of Fudan University
Chronic Spontaneous Urticaria
Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)
Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to escalate/switch current treatment to remibrutinib.
- Trial name
- NCT07642557
- Where
- Germany
- Volunteers
- 470 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetes
The purpose of the study is to assess the safety and efficacy of a next generation automated insulin delivery algorithm in adults with type 2 diabetes aged 16-70 years old
- Trial name
- NCT07039981
- Testing
- Omnipod M system
- Where
- 2 sites in New Zealand
- Volunteers
- 48 people
- Sponsor
- Insulet Corporation
Febrile Neutropenia
Next-Generation-Sequencing Approach to Neutropenic Sepsis
The aim of this prospective, observational, non-interventional, multi-centre study of the diagnostic use of DISQVER in neutropenic patients with FN is to provide further evidence of the efficacy of an NGS-based approach for…
- Trial name
- NEXUS (NCT05815628)
- Testing
- DISQVER
- Where
- 6 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Boris Böll
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome
Acute coronary syndrome (ACS) guidelines have been changed, favoring dual antiplatelet therapy (DAPT) with the more potent P2Y12 inhibitor ticagrelor over clopidogrel (besides aspirin).
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Drug-Eluting Stents
- Trial name
- CHANGE DAPT (NCT03197298)
- Testing
- Clopidogrel, Ticagrelor
- Where
- Netherlands
- Volunteers
- 2,062 people
- Sponsor
- Thorax Centrum Twente
Chronic Spontaneous Urticaria (CSU)
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily [b.i.d.] by mouth [p.o.]) compared to dupilumab (600 mg loading dose administered…
- Trial name
- RECLAIM (NCT06868212)
- Testing
- Remibrutinib, Dupilumab
- Where
- 121 sites in United States
- Volunteers
- 409 people
- Sponsor
- Novartis Pharmaceuticals
Essential Tremor
Next-Generation Pre-Operative Targeting for Thalamic DBS in the Treatment of Tremor
Researchers are investigating improved methods of targeting deep brain stimulators for treatment of essential tremor relying on brain connectivity measures derived from MRI.
- Trial name
- NCT03875404
- Testing
- Functional MRI
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Third-generation TKI, NSCLC (Advanced Non-small Cell Lung Cancer)
Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC
The goal of this observational study is to explore the feasibility of stereotactic radiotherapy (SRT) as consolidation therapy for patients with advanced non-small-cell lung cancer who were treated with third-generation epidermal…
- Trial name
- NCT06613633
- Testing
- third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)
- Where
- 3 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Fudan University
de Novo Lesions in Native Coronary Arteries
First in Man Trial - BIOSOLVE-I
First in Man Trial with the drug eluting absorbable metal scaffold. To assess safety
- Trial name
- BIOSOLVE-I (NCT01168830)
- Testing
- AMS-3.0
- Where
- 6 sites in Belgium, Germany and 2 more
- Volunteers
- 46 people
- Sponsor
- Biotronik AG
Pulmonary Fibrosis
A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
This study is open to adults aged 18 years and older who have pulmonary fibrosis with or without a known cause (or other forms of pulmonary fibrosis).
- Trial name
- NCT05670587
- Testing
- A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
Waldenstrom Macroglobulinemia
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
This is a multi-centre, open label, single-arm, phase II clinical trial in untreated patients with Waldenstrom's Macroglobulinemia.
- Trial name
- BRAWM (NCT04624906)
- Testing
- Acalabrutinib, Bendamustine, Rituximab
- Where
- 9 sites in Canada
- Volunteers
- 63 people
- Sponsor
- Sunnybrook Health Sciences Centre
Primary Central Nervous System Lymphoma
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma
To observe the efficacy and safety of a new generation of BTK inhibitor Orelabrutinib combined with PD-1 and fotemustine in the treatment of patients with primary central nervous system lymphoma (PCNSL).
- Trial name
- NCT04831658
- Testing
- the dose-escalation phase
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Mingzhi Zhang
Coronary Artery Disease
Drug-Coated Balloon in Combination With New Generation Drug-Eluting Stent for de Novo Diffuse Disease Treatment
A Pilot Observational Study to evaluate safety and efficacy of the hybrid approach DES/DCB in treating de-novo diffuse lesions
- Trial name
- HYPER (NCT03939468)
- Testing
- DES+DCB
- Where
- 6 sites in Italy
- Volunteers
- 106 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.